Global Antiproliferative Drugs Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 123

Published Date: 01 Apr 2022

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Antiproliferative Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Antiproliferative Drugs market size is estimated to be worth US$  million in 2021 and is forecast to a readjusted size of USD  million by 2028 with a CAGR of  % during forecast period 2022-2028. Clinic accounting for  % of the Antiproliferative Drugs global market in 2021, is projected to value USD  million by 2028, growing at a  % CAGR in next six years. While Mycophenolate Mofetil segment is altered to a  % CAGR between 2022 and 2028.

Global key companies of Antiproliferative Drugs include Accord Healthcare, F. Hoffmann-La Roche, Novartis AG, Mylan N.V., and Astellas Pharma, etc. In terms of revenue, the global top four players hold a share over  % in 2021.

Market segmentation
Antiproliferative Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    Mycophenolate Mofetil
    Mycophenolate Sodium
    Azathioprine

Market segment by Application, can be divided into
    Clinic
    Hospital
    Others

Market segment by players, this report covers
    Accord Healthcare
    F. Hoffmann-La Roche
    Novartis AG
    Mylan N.V.
    Astellas Pharma
    Pfizer
    Glenmark Pharmaceuticals Limited
    Zydus Cadila
    Bristol-Myers Squibb Company
    GlaxoSmithKline
    Sanofi
    Allergan
    AbbVie
    Cipla
    Johnson & Johnson Private Limited
    Teva Pharmaceutical Industries
    Veloxis Pharmaceuticals
    Eli Lilly and Company
    Lupin
    AstraZeneca

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Antiproliferative Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Antiproliferative Drugs, with revenue, gross margin and global market share of Antiproliferative Drugs from 2019 to 2022.
Chapter 3, the Antiproliferative Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Antiproliferative Drugs market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Antiproliferative Drugs research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Antiproliferative Drugs
    1.2 Classification of Antiproliferative Drugs by Type
        1.2.1 Overview: Global Antiproliferative Drugs Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Antiproliferative Drugs Revenue Market Share by Type in 2021
        1.2.3 Mycophenolate Mofetil
        1.2.4 Mycophenolate Sodium
        1.2.5 Azathioprine
    1.3 Global Antiproliferative Drugs Market by Application
        1.3.1 Overview: Global Antiproliferative Drugs Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 Global Antiproliferative Drugs Market Size & Forecast
    1.5 Global Antiproliferative Drugs Market Size and Forecast by Region
        1.5.1 Global Antiproliferative Drugs Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Antiproliferative Drugs Market Size by Region, (2017-2022)
        1.5.3 North America Antiproliferative Drugs Market Size and Prospect (2017-2028)
        1.5.4 Europe Antiproliferative Drugs Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Antiproliferative Drugs Market Size and Prospect (2017-2028)
        1.5.6 South America Antiproliferative Drugs Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Antiproliferative Drugs Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Antiproliferative Drugs Market Drivers
        1.6.2 Antiproliferative Drugs Market Restraints
        1.6.3 Antiproliferative Drugs Trends Analysis

2 Company Profiles
    2.1 Accord Healthcare
        2.1.1 Accord Healthcare Details
        2.1.2 Accord Healthcare Major Business
        2.1.3 Accord Healthcare Antiproliferative Drugs Product and Solutions
        2.1.4 Accord Healthcare Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 Accord Healthcare Recent Developments and Future Plans
    2.2 F. Hoffmann-La Roche
        2.2.1 F. Hoffmann-La Roche Details
        2.2.2 F. Hoffmann-La Roche Major Business
        2.2.3 F. Hoffmann-La Roche Antiproliferative Drugs Product and Solutions
        2.2.4 F. Hoffmann-La Roche Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 F. Hoffmann-La Roche Recent Developments and Future Plans
    2.3 Novartis AG
        2.3.1 Novartis AG Details
        2.3.2 Novartis AG Major Business
        2.3.3 Novartis AG Antiproliferative Drugs Product and Solutions
        2.3.4 Novartis AG Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 Novartis AG Recent Developments and Future Plans
    2.4 Mylan N.V.
        2.4.1 Mylan N.V. Details
        2.4.2 Mylan N.V. Major Business
        2.4.3 Mylan N.V. Antiproliferative Drugs Product and Solutions
        2.4.4 Mylan N.V. Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Mylan N.V. Recent Developments and Future Plans
    2.5 Astellas Pharma
        2.5.1 Astellas Pharma Details
        2.5.2 Astellas Pharma Major Business
        2.5.3 Astellas Pharma Antiproliferative Drugs Product and Solutions
        2.5.4 Astellas Pharma Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Astellas Pharma Recent Developments and Future Plans
    2.6 Pfizer
        2.6.1 Pfizer Details
        2.6.2 Pfizer Major Business
        2.6.3 Pfizer Antiproliferative Drugs Product and Solutions
        2.6.4 Pfizer Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Pfizer Recent Developments and Future Plans
    2.7 Glenmark Pharmaceuticals Limited
        2.7.1 Glenmark Pharmaceuticals Limited Details
        2.7.2 Glenmark Pharmaceuticals Limited Major Business
        2.7.3 Glenmark Pharmaceuticals Limited Antiproliferative Drugs Product and Solutions
        2.7.4 Glenmark Pharmaceuticals Limited Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 Glenmark Pharmaceuticals Limited Recent Developments and Future Plans
    2.8 Zydus Cadila
        2.8.1 Zydus Cadila Details
        2.8.2 Zydus Cadila Major Business
        2.8.3 Zydus Cadila Antiproliferative Drugs Product and Solutions
        2.8.4 Zydus Cadila Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Zydus Cadila Recent Developments and Future Plans
    2.9 Bristol-Myers Squibb Company
        2.9.1 Bristol-Myers Squibb Company Details
        2.9.2 Bristol-Myers Squibb Company Major Business
        2.9.3 Bristol-Myers Squibb Company Antiproliferative Drugs Product and Solutions
        2.9.4 Bristol-Myers Squibb Company Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
    2.10 GlaxoSmithKline
        2.10.1 GlaxoSmithKline Details
        2.10.2 GlaxoSmithKline Major Business
        2.10.3 GlaxoSmithKline Antiproliferative Drugs Product and Solutions
        2.10.4 GlaxoSmithKline Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 GlaxoSmithKline Recent Developments and Future Plans
    2.11 Sanofi
        2.11.1 Sanofi Details
        2.11.2 Sanofi Major Business
        2.11.3 Sanofi Antiproliferative Drugs Product and Solutions
        2.11.4 Sanofi Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.11.5 Sanofi Recent Developments and Future Plans
    2.12 Allergan
        2.12.1 Allergan Details
        2.12.2 Allergan Major Business
        2.12.3 Allergan Antiproliferative Drugs Product and Solutions
        2.12.4 Allergan Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.12.5 Allergan Recent Developments and Future Plans
    2.13 AbbVie
        2.13.1 AbbVie Details
        2.13.2 AbbVie Major Business
        2.13.3 AbbVie Antiproliferative Drugs Product and Solutions
        2.13.4 AbbVie Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.13.5 AbbVie Recent Developments and Future Plans
    2.14 Cipla
        2.14.1 Cipla Details
        2.14.2 Cipla Major Business
        2.14.3 Cipla Antiproliferative Drugs Product and Solutions
        2.14.4 Cipla Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.14.5 Cipla Recent Developments and Future Plans
    2.15 Johnson & Johnson Private Limited
        2.15.1 Johnson & Johnson Private Limited Details
        2.15.2 Johnson & Johnson Private Limited Major Business
        2.15.3 Johnson & Johnson Private Limited Antiproliferative Drugs Product and Solutions
        2.15.4 Johnson & Johnson Private Limited Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.15.5 Johnson & Johnson Private Limited Recent Developments and Future Plans
    2.16 Teva Pharmaceutical Industries
        2.16.1 Teva Pharmaceutical Industries Details
        2.16.2 Teva Pharmaceutical Industries Major Business
        2.16.3 Teva Pharmaceutical Industries Antiproliferative Drugs Product and Solutions
        2.16.4 Teva Pharmaceutical Industries Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.16.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
    2.17 Veloxis Pharmaceuticals
        2.17.1 Veloxis Pharmaceuticals Details
        2.17.2 Veloxis Pharmaceuticals Major Business
        2.17.3 Veloxis Pharmaceuticals Antiproliferative Drugs Product and Solutions
        2.17.4 Veloxis Pharmaceuticals Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.17.5 Veloxis Pharmaceuticals Recent Developments and Future Plans
    2.18 Eli Lilly and Company
        2.18.1 Eli Lilly and Company Details
        2.18.2 Eli Lilly and Company Major Business
        2.18.3 Eli Lilly and Company Antiproliferative Drugs Product and Solutions
        2.18.4 Eli Lilly and Company Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.18.5 Eli Lilly and Company Recent Developments and Future Plans
    2.19 Lupin
        2.19.1 Lupin Details
        2.19.2 Lupin Major Business
        2.19.3 Lupin Antiproliferative Drugs Product and Solutions
        2.19.4 Lupin Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.19.5 Lupin Recent Developments and Future Plans
    2.20 AstraZeneca
        2.20.1 AstraZeneca Details
        2.20.2 AstraZeneca Major Business
        2.20.3 AstraZeneca Antiproliferative Drugs Product and Solutions
        2.20.4 AstraZeneca Antiproliferative Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.20.5 AstraZeneca Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Antiproliferative Drugs Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Antiproliferative Drugs Players Market Share in 2021
        3.2.2 Top 10 Antiproliferative Drugs Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Antiproliferative Drugs Players Head Office, Products and Services Provided
    3.4 Antiproliferative Drugs Mergers & Acquisitions
    3.5 Antiproliferative Drugs New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global Antiproliferative Drugs Revenue and Market Share by Type (2017-2022)
    4.2 Global Antiproliferative Drugs Market Forecast by Type (2023-2028)

5 Market Size Segment by Application
    5.1 Global Antiproliferative Drugs Revenue Market Share by Application (2017-2022)
    5.2 Global Antiproliferative Drugs Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application
    6.1 North America Antiproliferative Drugs Revenue by Type (2017-2028)
    6.2 North America Antiproliferative Drugs Revenue by Application (2017-2028)
    6.3 North America Antiproliferative Drugs Market Size by Country
        6.3.1 North America Antiproliferative Drugs Revenue by Country (2017-2028)
        6.3.2 United States Antiproliferative Drugs Market Size and Forecast (2017-2028)
        6.3.3 Canada Antiproliferative Drugs Market Size and Forecast (2017-2028)
        6.3.4 Mexico Antiproliferative Drugs Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application
    7.1 Europe Antiproliferative Drugs Revenue by Type (2017-2028)
    7.2 Europe Antiproliferative Drugs Revenue by Application (2017-2028)
    7.3 Europe Antiproliferative Drugs Market Size by Country
        7.3.1 Europe Antiproliferative Drugs Revenue by Country (2017-2028)
        7.3.2 Germany Antiproliferative Drugs Market Size and Forecast (2017-2028)
        7.3.3 France Antiproliferative Drugs Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Antiproliferative Drugs Market Size and Forecast (2017-2028)
        7.3.5 Russia Antiproliferative Drugs Market Size and Forecast (2017-2028)
        7.3.6 Italy Antiproliferative Drugs Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Antiproliferative Drugs Revenue by Type (2017-2028)
    8.2 Asia-Pacific Antiproliferative Drugs Revenue by Application (2017-2028)
    8.3 Asia-Pacific Antiproliferative Drugs Market Size by Region
        8.3.1 Asia-Pacific Antiproliferative Drugs Revenue by Region (2017-2028)
        8.3.2 China Antiproliferative Drugs Market Size and Forecast (2017-2028)
        8.3.3 Japan Antiproliferative Drugs Market Size and Forecast (2017-2028)
        8.3.4 South Korea Antiproliferative Drugs Market Size and Forecast (2017-2028)
        8.3.5 India Antiproliferative Drugs Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Antiproliferative Drugs Market Size and Forecast (2017-2028)
        8.3.7 Australia Antiproliferative Drugs Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application
    9.1 South America Antiproliferative Drugs Revenue by Type (2017-2028)
    9.2 South America Antiproliferative Drugs Revenue by Application (2017-2028)
    9.3 South America Antiproliferative Drugs Market Size by Country
        9.3.1 South America Antiproliferative Drugs Revenue by Country (2017-2028)
        9.3.2 Brazil Antiproliferative Drugs Market Size and Forecast (2017-2028)
        9.3.3 Argentina Antiproliferative Drugs Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Antiproliferative Drugs Revenue by Type (2017-2028)
    10.2 Middle East & Africa Antiproliferative Drugs Revenue by Application (2017-2028)
    10.3 Middle East & Africa Antiproliferative Drugs Market Size by Country
        10.3.1 Middle East & Africa Antiproliferative Drugs Revenue by Country (2017-2028)
        10.3.2 Turkey Antiproliferative Drugs Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Antiproliferative Drugs Market Size and Forecast (2017-2028)
        10.3.4 UAE Antiproliferative Drugs Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Antiproliferative Drugs Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
    Table 2. Global Antiproliferative Drugs Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
    Table 3. Global Market Antiproliferative Drugs Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
    Table 4. Global Antiproliferative Drugs Revenue (USD Million) by Region (2017-2022)
    Table 5. Global Antiproliferative Drugs Revenue Market Share by Region (2023-2028)
    Table 6. Accord Healthcare Corporate Information, Head Office, and Major Competitors
    Table 7. Accord Healthcare Major Business
    Table 8. Accord Healthcare Antiproliferative Drugs Product and Solutions
    Table 9. Accord Healthcare Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 10. F. Hoffmann-La Roche Corporate Information, Head Office, and Major Competitors
    Table 11. F. Hoffmann-La Roche Major Business
    Table 12. F. Hoffmann-La Roche Antiproliferative Drugs Product and Solutions
    Table 13. F. Hoffmann-La Roche Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 14. Novartis AG Corporate Information, Head Office, and Major Competitors
    Table 15. Novartis AG Major Business
    Table 16. Novartis AG Antiproliferative Drugs Product and Solutions
    Table 17. Novartis AG Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 18. Mylan N.V. Corporate Information, Head Office, and Major Competitors
    Table 19. Mylan N.V. Major Business
    Table 20. Mylan N.V. Antiproliferative Drugs Product and Solutions
    Table 21. Mylan N.V. Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 22. Astellas Pharma Corporate Information, Head Office, and Major Competitors
    Table 23. Astellas Pharma Major Business
    Table 24. Astellas Pharma Antiproliferative Drugs Product and Solutions
    Table 25. Astellas Pharma Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 26. Pfizer Corporate Information, Head Office, and Major Competitors
    Table 27. Pfizer Major Business
    Table 28. Pfizer Antiproliferative Drugs Product and Solutions
    Table 29. Pfizer Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 30. Glenmark Pharmaceuticals Limited Corporate Information, Head Office, and Major Competitors
    Table 31. Glenmark Pharmaceuticals Limited Major Business
    Table 32. Glenmark Pharmaceuticals Limited Antiproliferative Drugs Product and Solutions
    Table 33. Glenmark Pharmaceuticals Limited Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 34. Zydus Cadila Corporate Information, Head Office, and Major Competitors
    Table 35. Zydus Cadila Major Business
    Table 36. Zydus Cadila Antiproliferative Drugs Product and Solutions
    Table 37. Zydus Cadila Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 38. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
    Table 39. Bristol-Myers Squibb Company Major Business
    Table 40. Bristol-Myers Squibb Company Antiproliferative Drugs Product and Solutions
    Table 41. Bristol-Myers Squibb Company Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 42. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
    Table 43. GlaxoSmithKline Major Business
    Table 44. GlaxoSmithKline Antiproliferative Drugs Product and Solutions
    Table 45. GlaxoSmithKline Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 46. Sanofi Corporate Information, Head Office, and Major Competitors
    Table 47. Sanofi Major Business
    Table 48. Sanofi Antiproliferative Drugs Product and Solutions
    Table 49. Sanofi Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 50. Allergan Corporate Information, Head Office, and Major Competitors
    Table 51. Allergan Major Business
    Table 52. Allergan Antiproliferative Drugs Product and Solutions
    Table 53. Allergan Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 54. AbbVie Corporate Information, Head Office, and Major Competitors
    Table 55. AbbVie Major Business
    Table 56. AbbVie Antiproliferative Drugs Product and Solutions
    Table 57. AbbVie Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 58. Cipla Corporate Information, Head Office, and Major Competitors
    Table 59. Cipla Major Business
    Table 60. Cipla Antiproliferative Drugs Product and Solutions
    Table 61. Cipla Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 62. Johnson & Johnson Private Limited Corporate Information, Head Office, and Major Competitors
    Table 63. Johnson & Johnson Private Limited Major Business
    Table 64. Johnson & Johnson Private Limited Antiproliferative Drugs Product and Solutions
    Table 65. Johnson & Johnson Private Limited Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 66. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
    Table 67. Teva Pharmaceutical Industries Major Business
    Table 68. Teva Pharmaceutical Industries Antiproliferative Drugs Product and Solutions
    Table 69. Teva Pharmaceutical Industries Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 70. Veloxis Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 71. Veloxis Pharmaceuticals Major Business
    Table 72. Veloxis Pharmaceuticals Antiproliferative Drugs Product and Solutions
    Table 73. Veloxis Pharmaceuticals Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 74. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
    Table 75. Eli Lilly and Company Major Business
    Table 76. Eli Lilly and Company Antiproliferative Drugs Product and Solutions
    Table 77. Eli Lilly and Company Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 78. Lupin Corporate Information, Head Office, and Major Competitors
    Table 79. Lupin Major Business
    Table 80. Lupin Antiproliferative Drugs Product and Solutions
    Table 81. Lupin Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 82. AstraZeneca Corporate Information, Head Office, and Major Competitors
    Table 83. AstraZeneca Major Business
    Table 84. AstraZeneca Antiproliferative Drugs Product and Solutions
    Table 85. AstraZeneca Antiproliferative Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 86. Global Antiproliferative Drugs Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
    Table 87. Global Antiproliferative Drugs Revenue Share by Players (2019, 2020, 2021, and 2022)
    Table 88. Breakdown of Antiproliferative Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 89. Antiproliferative Drugs Players Head Office, Products and Services Provided
    Table 90. Antiproliferative Drugs Mergers & Acquisitions in the Past Five Years
    Table 91. Antiproliferative Drugs New Entrants and Expansion Plans
    Table 92. Global Antiproliferative Drugs Revenue (USD Million) by Type (2017-2022)
    Table 93. Global Antiproliferative Drugs Revenue Share by Type (2017-2022)
    Table 94. Global Antiproliferative Drugs Revenue Forecast by Type (2023-2028)
    Table 95. Global Antiproliferative Drugs Revenue by Application (2017-2022)
    Table 96. Global Antiproliferative Drugs Revenue Forecast by Application (2023-2028)
    Table 97. North America Antiproliferative Drugs Revenue by Type (2017-2022) & (USD Million)
    Table 98. North America Antiproliferative Drugs Revenue by Type (2023-2028) & (USD Million)
    Table 99. North America Antiproliferative Drugs Revenue by Application (2017-2022) & (USD Million)
    Table 100. North America Antiproliferative Drugs Revenue by Application (2023-2028) & (USD Million)
    Table 101. North America Antiproliferative Drugs Revenue by Country (2017-2022) & (USD Million)
    Table 102. North America Antiproliferative Drugs Revenue by Country (2023-2028) & (USD Million)
    Table 103. Europe Antiproliferative Drugs Revenue by Type (2017-2022) & (USD Million)
    Table 104. Europe Antiproliferative Drugs Revenue by Type (2023-2028) & (USD Million)
    Table 105. Europe Antiproliferative Drugs Revenue by Application (2017-2022) & (USD Million)
    Table 106. Europe Antiproliferative Drugs Revenue by Application (2023-2028) & (USD Million)
    Table 107. Europe Antiproliferative Drugs Revenue by Country (2017-2022) & (USD Million)
    Table 108. Europe Antiproliferative Drugs Revenue by Country (2023-2028) & (USD Million)
    Table 109. Asia-Pacific Antiproliferative Drugs Revenue by Type (2017-2022) & (USD Million)
    Table 110. Asia-Pacific Antiproliferative Drugs Revenue by Type (2023-2028) & (USD Million)
    Table 111. Asia-Pacific Antiproliferative Drugs Revenue by Application (2017-2022) & (USD Million)
    Table 112. Asia-Pacific Antiproliferative Drugs Revenue by Application (2023-2028) & (USD Million)
    Table 113. Asia-Pacific Antiproliferative Drugs Revenue by Region (2017-2022) & (USD Million)
    Table 114. Asia-Pacific Antiproliferative Drugs Revenue by Region (2023-2028) & (USD Million)
    Table 115. South America Antiproliferative Drugs Revenue by Type (2017-2022) & (USD Million)
    Table 116. South America Antiproliferative Drugs Revenue by Type (2023-2028) & (USD Million)
    Table 117. South America Antiproliferative Drugs Revenue by Application (2017-2022) & (USD Million)
    Table 118. South America Antiproliferative Drugs Revenue by Application (2023-2028) & (USD Million)
    Table 119. South America Antiproliferative Drugs Revenue by Country (2017-2022) & (USD Million)
    Table 120. South America Antiproliferative Drugs Revenue by Country (2023-2028) & (USD Million)
    Table 121. Middle East & Africa Antiproliferative Drugs Revenue by Type (2017-2022) & (USD Million)
    Table 122. Middle East & Africa Antiproliferative Drugs Revenue by Type (2023-2028) & (USD Million)
    Table 123. Middle East & Africa Antiproliferative Drugs Revenue by Application (2017-2022) & (USD Million)
    Table 124. Middle East & Africa Antiproliferative Drugs Revenue by Application (2023-2028) & (USD Million)
    Table 125. Middle East & Africa Antiproliferative Drugs Revenue by Country (2017-2022) & (USD Million)
    Table 126. Middle East & Africa Antiproliferative Drugs Revenue by Country (2023-2028) & (USD Million)
List of Figures
    Figure 1. Antiproliferative Drugs Picture
    Figure 2. Global Antiproliferative Drugs Revenue Market Share by Type in 2021
    Figure 3. Mycophenolate Mofetil
    Figure 4. Mycophenolate Sodium
    Figure 5. Azathioprine
    Figure 6. Antiproliferative Drugs Revenue Market Share by Application in 2021
    Figure 7. Clinic Picture
    Figure 8. Hospital Picture
    Figure 9. Others Picture
    Figure 10. Global Antiproliferative Drugs Market Size, (USD Million): 2017 VS 2021 VS 2028
    Figure 11. Global Antiproliferative Drugs Revenue and Forecast (2017-2028) & (USD Million)
    Figure 12. Global Antiproliferative Drugs Revenue Market Share by Region (2017-2028)
    Figure 13. Global Antiproliferative Drugs Revenue Market Share by Region in 2021
    Figure 14. North America Antiproliferative Drugs Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 15. Europe Antiproliferative Drugs Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 16. Asia-Pacific Antiproliferative Drugs Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 17. South America Antiproliferative Drugs Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 18. Middle East and Africa Antiproliferative Drugs Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 19. Antiproliferative Drugs Market Drivers
    Figure 20. Antiproliferative Drugs Market Restraints
    Figure 21. Antiproliferative Drugs Market Trends
    Figure 22. Accord Healthcare Recent Developments and Future Plans
    Figure 23. F. Hoffmann-La Roche Recent Developments and Future Plans
    Figure 24. Novartis AG Recent Developments and Future Plans
    Figure 25. Mylan N.V. Recent Developments and Future Plans
    Figure 26. Astellas Pharma Recent Developments and Future Plans
    Figure 27. Pfizer Recent Developments and Future Plans
    Figure 28. Glenmark Pharmaceuticals Limited Recent Developments and Future Plans
    Figure 29. Zydus Cadila Recent Developments and Future Plans
    Figure 30. Bristol-Myers Squibb Company Recent Developments and Future Plans
    Figure 31. GlaxoSmithKline Recent Developments and Future Plans
    Figure 32. Sanofi Recent Developments and Future Plans
    Figure 33. Allergan Recent Developments and Future Plans
    Figure 34. AbbVie Recent Developments and Future Plans
    Figure 35. Cipla Recent Developments and Future Plans
    Figure 36. Johnson & Johnson Private Limited Recent Developments and Future Plans
    Figure 37. Teva Pharmaceutical Industries Recent Developments and Future Plans
    Figure 38. Veloxis Pharmaceuticals Recent Developments and Future Plans
    Figure 39. Eli Lilly and Company Recent Developments and Future Plans
    Figure 40. Lupin Recent Developments and Future Plans
    Figure 41. AstraZeneca Recent Developments and Future Plans
    Figure 42. Global Antiproliferative Drugs Revenue Share by Players in 2021
    Figure 43. Antiproliferative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
    Figure 44. Global Top 3 Players Antiproliferative Drugs Revenue Market Share in 2021
    Figure 45. Global Top 10 Players Antiproliferative Drugs Revenue Market Share in 2021
    Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
    Figure 47. Global Antiproliferative Drugs Revenue Share by Type in 2021
    Figure 48. Global Antiproliferative Drugs Market Share Forecast by Type (2023-2028)
    Figure 49. Global Antiproliferative Drugs Revenue Share by Application in 2021
    Figure 50. Global Antiproliferative Drugs Market Share Forecast by Application (2023-2028)
    Figure 51. North America Antiproliferative Drugs Sales Market Share by Type (2017-2028)
    Figure 52. North America Antiproliferative Drugs Sales Market Share by Application (2017-2028)
    Figure 53. North America Antiproliferative Drugs Revenue Market Share by Country (2017-2028)
    Figure 54. United States Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 55. Canada Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 56. Mexico Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 57. Europe Antiproliferative Drugs Sales Market Share by Type (2017-2028)
    Figure 58. Europe Antiproliferative Drugs Sales Market Share by Application (2017-2028)
    Figure 59. Europe Antiproliferative Drugs Revenue Market Share by Country (2017-2028)
    Figure 60. Germany Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 61. France Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 62. United Kingdom Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 63. Russia Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 64. Italy Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 65. Asia-Pacific Antiproliferative Drugs Sales Market Share by Type (2017-2028)
    Figure 66. Asia-Pacific Antiproliferative Drugs Sales Market Share by Application (2017-2028)
    Figure 67. Asia-Pacific Antiproliferative Drugs Revenue Market Share by Region (2017-2028)
    Figure 68. China Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 69. Japan Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 70. South Korea Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 71. India Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 72. Southeast Asia Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 73. Australia Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 74. South America Antiproliferative Drugs Sales Market Share by Type (2017-2028)
    Figure 75. South America Antiproliferative Drugs Sales Market Share by Application (2017-2028)
    Figure 76. South America Antiproliferative Drugs Revenue Market Share by Country (2017-2028)
    Figure 77. Brazil Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 78. Argentina Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 79. Middle East and Africa Antiproliferative Drugs Sales Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Antiproliferative Drugs Sales Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Antiproliferative Drugs Revenue Market Share by Country (2017-2028)
    Figure 82. Turkey Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 83. Saudi Arabia Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 84. UAE Antiproliferative Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 85. Methodology
    Figure 86. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Accord Healthcare
F. Hoffmann-La Roche
Novartis AG
Mylan N.V.
Astellas Pharma
Pfizer
Glenmark Pharmaceuticals Limited
Zydus Cadila
Bristol-Myers Squibb Company
GlaxoSmithKline
Sanofi
Allergan
AbbVie
Cipla
Johnson & Johnson Private Limited
Teva Pharmaceutical Industries
Veloxis Pharmaceuticals
Eli Lilly and Company
Lupin
AstraZeneca

Related Reports

Global Antiproliferative Drugs Supply, Demand and Key Producers, 2023-2029

Global Antiproliferative Drugs Supply, Demand and Key Producers, 2023-2029

date 13 Feb 2023

date Medical Care

The global Antiproliferative Drugs market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Antiproliferative Drugs Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Antiproliferative Drugs Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 02 Jan 2023

date Medical Care

Antiproliferative drugs are the type of immunosuppressive medication that works by blocking cell-cycle pathways, limiting the T- and B-cell proliferation and thereby lowering the cytotoxic response aimed at the cardiac allograft. It is also termed as antimetabolites. Immunosuppressants are a type of medication that helps to suppress the immune system's response to foreign substances. These medications limit the immune response and safeguard the new organ and its function, prevent organ rejection. They're most commonly used to prevent autoimmune illnesses such as arthritis, myasthenia gravis, Crohn's disease, lupus, rheumatoid arthritis, and organ transplant rejections like kidney, liver, and heart transplants.

Global Antiproliferative Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Antiproliferative Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 20 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global Antiproliferative Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

antiproliferative drugs

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>